Cargando…

Differential residual dyslipidemia/cardiovascular risk after statin treatment between Asian-Indians and western whites. Call for action

Detalles Bibliográficos
Autores principales:	Athyros, Vasilios Gabriel, Doumas, Michael, Karagiannis, Asterios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079131/ https://www.ncbi.nlm.nih.gov/pubmed/27773395 http://dx.doi.org/10.1016/j.ihj.2016.02.022

Ejemplares similares

Off target effects of statins shape total mortality?
por: Athyros, Vasilios G., et al.
Publicado: (2016)

Dyslipidaemia of Obesity, Metabolic Syndrome and Type 2 Diabetes Mellitus: the Case for Residual Risk Reduction After Statin Treatment
por: Athyros, Vasilios G, et al.
Publicado: (2011)

Dyslipidemia Induced by Drugs Used for the Prevention and Treatment of Vascular Diseases
por: Tziomalos, Konstantinos, et al.
Publicado: (2011)

Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?
por: Athyros, Vasilios G, et al.
Publicado: (2011)

Suboptimal management of dyslipidemia in everyday clinical practice: Alarming signals from real-world data
por: Athyros, Vasilios G., et al.
Publicado: (2020)

Single-pill combinations: a therapeutic option or necessity for vascular risk treatment?
por: Katsiki, Niki, et al.
Publicado: (2013)

Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study
por: Athyros, Vasilios G., et al.
Publicado: (2013)

The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings
por: Athyros, Vasilios G., et al.
Publicado: (2012)

Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients(§)
por: Athyros, Vasilios G, et al.
Publicado: (2007)

Is There a Role for Hypolipidaemic Drug Therapy in the Prevention or Treatment of Microvascular Complications of Diabetes?
por: Mitsiou, Eydoxia K, et al.
Publicado: (2012)

Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?
por: Athyros, Vasilios G., et al.
Publicado: (2011)

Is There an Association Between Carotid-Femoral Pulse Wave Velocity and Coronary Heart Disease in Patients with Coronary Artery Disease: A Pilot Study
por: Katsiki, Niki, et al.
Publicado: (2016)

Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?
por: Reklou, Andromachi, et al.
Publicado: (2018)

Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Statin therapy/lipid lowering therapy among Indian adults with first acute coronary event: The dyslipidemia Residual and Mixed Abnormalities IN spite of Statin therapy (REMAINS) study
por: Jaywant, Salgaonkar V., et al.
Publicado: (2016)

Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Colchicine for the prevention of COVID-19 “hard” outcomes: All that glitters is not gold
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Sodium-glucose co-transporter-2 inhibitor mediated cardio-protection: does increase of hematocrit finally matter? Sub-analysis of a prospective, observational study
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study
por: Anagnostis, Panagiotis, et al.
Publicado: (2014)

Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia
por: Meikle, Peter J., et al.
Publicado: (2015)

The role of dyslipidemia and statins in venous thromboembolism
por: Ray, Joel G, et al.
Publicado: (2001)

IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis
por: Athyros, Vasilios G., et al.
Publicado: (2011)

Are we getting to lipid targets in real life?
por: Katsiki, Niki, et al.
Publicado: (2010)

COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?
por: Doumas, Michael, et al.
Publicado: (2020)

Obesity and Dyslipidemia in South Asians
por: Misra, Anoop, et al.
Publicado: (2013)

New Drugs for Treating Dyslipidemia: Beyond Statins
por: Ahn, Chang Ho, et al.
Publicado: (2015)

Prevalence and types of persistent dyslipidemia in patients treated with statins
por: Reiner, Željko, et al.
Publicado: (2013)

Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study
por: Azar, Sami T, et al.
Publicado: (2014)

Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study
por: Athyros, Vassilios G., et al.
Publicado: (2011)

Impact of metformin on statin‐associated myopathy risks in dyslipidemia patients
por: Bak, Keunhyeong, et al.
Publicado: (2023)

Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
por: Lee, Jeongmin, et al.
Publicado: (2023)

Comparison of ambulatory central hemodynamics and arterial stiffness in patients with diabetic and non‐diabetic CKD
por: Loutradis, Charalampos, et al.
Publicado: (2020)

Statin Intolerance—An Asian Perspective
por: Tomlinson, Brian, et al.
Publicado: (2020)

Time to consider an Asian guideline for management of dyslipidemia?
por: Yokote, Koutaro, et al.
Publicado: (2012)

Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

Fenofibrate: a novel formulation (Triglide™) in the treatment of lipid disorders: a review
por: Tziomalos, Konstantinos, et al.
Publicado: (2006)

Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia
por: Benes, Lane B, et al.
Publicado: (2016)

The Asian Federation of Osteoporosis Societies' call to action to improve the undertreatment of osteoporosis in Asia
por: Yeap, Swan Sim, et al.
Publicado: (2017)

Psychological Distress Among Asian Indians and Non-Hispanic Whites in the United States
por: Siddiqui, Zasim Azhar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kglmlhs1gcvqbvl48usf6lgjsh